What is Cellectar Biosciences?
Cellectar Biosciences, Inc. is dedicated to the discovery, development, and commercialization of innovative drugs for cancer treatment. The company's lead candidate, CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), is currently undergoing Phase 2 clinical studies for various B-cell malignancies, including relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma. Additionally, Phase 1 studies are exploring its efficacy in pediatric patients with select solid tumors and lymphomas, as well as in head and neck cancer patients. The company's pipeline targets unmet needs in oncology, aiming to provide new therapeutic options for patients with difficult-to-treat cancers.
How much funding has Cellectar Biosciences raised?
Cellectar Biosciences has raised a total of $199.6M across 14 funding rounds:
Stock Offering
$9.2M
Stock Offering
$7.8M
Stock Offering
$16.6M
Stock Offering
$10M
Debt
$150K
Share Placement
$102.9M
Stock/Share Issuance
$2.5M
Stock Issuance/Offering (2016): $9.2M supported by Ladenburg Thalmann & Co.
Stock Issuance/Offering (2017): $7.8M featuring Undisclosed
Stock Issuance/Offering (2018): $16.6M backed by Ladenburg Thalmann & Co.
Stock Issuance/Offering (2019): $10M with participation from Roth Capital Partners
Debt (2020): $150K led by PPP
Share Placement (2023): $102.9M supported by Second Line and Rosalind Advisors
Stock/Share Issuance (2025): $2.5M, investors not publicly disclosed
Key Investors in Cellectar Biosciences
Second Line
SecondLine offers virtual phone numbers and cloud-based communication features, catering to businesses seeking to enhance their global presence and communication efficiency.
Rosalind Advisors
Rosalind Advisors, Inc. specializes in life science investing and manages biotech funds, focusing on providing investment opportunities within the biotechnology sector.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
What's next for Cellectar Biosciences?
The substantial enterprise-level funding Cellectar Biosciences has attracted indicates a strong investor confidence in its clinical development pipeline and its potential to address critical needs in cancer therapy. This capital infusion is expected to accelerate the progression of CLR 131 through its ongoing clinical trials and support broader commercialization efforts. The company's strategic focus on PDCs positions it within a growing segment of targeted cancer treatments, suggesting a trajectory towards further growth and potential market penetration as clinical data matures and regulatory milestones are achieved.
See full Cellectar Biosciences company page
